Inactive

SOURCES SOUGHT NOTICE: To determine eligibility for enrollment in ETIB/NCI Clinical trials Notice Number: 75N91020Q00020 Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://... SOURCES SOUGHT NOTICE: To determine eligibility for enrollment in ETIB/NCI Clinical trials Notice Number: 75N91020Q00020 Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: January 28, 2020 by 12:00PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified Small Business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned businesses that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1000 employees. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI’s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The National Cancer Institute (NCI), Center for Cancer Research (CCR), Experimental Transplantation and Immunology Branch (ETIB) identified a T-cell receptor that targets the cancer testes antigen KK-LC-1 (also known as CT83) in a HLA-0101 restricted manner. This T-cell receptor is capable of killing tumors in-vitro and in-vivo, and furthermore has demonstrated negligible off-target effect in-vitro. This KK-LC-1 T- cell receptor will be tested in a Phase I ETIB/clinical trial. To determine if patients are eligible to be enrolled in this ETIB/NCI clinical trial, a RNAscope in-situ hybridization assay will be performed to check if patients express KK-LC-1. RNAscope is an RNA probe-based technology used to accurately identify RNA transcripts in cells. Specifically, NCI will use CT83 specific RNA probes to identify CT83 RNA transcripts in patient biopsies. Presence of more than or equal to 30% CT83 expression in the biopsies will be used for the inclusion criterion. A Bond RX machine is used to perform this RNAscope assay in an automated fashion. Previously a bond Rx machine was used to optimize CT83 RNAscope prior to starting the clinical trial. Acquiring a machine that is conducive to the RNAscope technique is critical to the success of this trial. The following salient features/characteristics are required for this equipment: Must be designed with RNAscope technique in mind to include 7 buffer washes, 2 protease treatments and single probe binding. Must provide easy access to the buffers, probes and detection systems at any time. Must accommodate Titration containers for volumes ranging from 20ul to 1ml. Must be programmable in order to adjust for the period of time the assay will be used, the volume of reagents required, and the frequency of reagent treatments to ensure flexibility of analysis and consistency of results. Must provide indicators revealing each stage of the assay process including reagent application, protocol progress monitoring and comprehensive reports. Must indicate quantity of buffers inside containers, probes and detection reagents. Must be able to hold up to 9 one-gallon containers that include a handle. Must include unique active lighting system. Must be able to operate automatically independent of manual labor. Must be able to complete the assay within 12 hours. Must dispense reagents while preserving morphology and integrity of precious tissue. Must be able to print out slide identifiers to label each separate biopsy sample. Must include scanner to identify each specific program. Must include uninterruptible power supply. A minimum 12-month manufacturer warranty must be included. Shipping/Handling costs must be included in the quote. NCI will not be responsible in the event charges are not included in the quote. Installation charges must be included in the quote. How to Submit a Response: Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12-point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a one page resume of the individuals meeting the requirements, and up to two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern’s name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. Organizations shall demonstrate 1.) Technical Approach 2.) Personnel Requirements and Organizational Experience. Due Date: Capability statements are due no later than January 28, 2020 by 12:00PM EST Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. All questions must be in writing and emailed to David.Romley@nih.gov. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. No collect calls will be accepted. Please reference number 75N91020Q00020 on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a RFQ may be published in Fed Biz Opps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: David Romley at David.Romley@nih.gov. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.